DSIP, delta sleep-inducing peptide, is a nonapeptide first isolated from rabbit blood in 1977 during electrically induced delta-wave sleep. Unlike Semax and Selank, it was studied mainly in Western Europe and has genuine blinded, placebo-controlled human trials from the 1980s and 1990s. Those trials did not demonstrate the clean, reproducible deep-sleep effect its name and modern marketing imply; the clearest finding across them is a modest drop in ACTH, not a sleep-architecture change. It has never been approved as a drug anywhere.
Ask about DSIP
Research snapshot
| Peptide category | Nonapeptide, first isolated from rabbit blood during delta-wave sleep |
| Primary research interest | Proposed sleep-induction effect (namesake use); actual controlled trials focused on HPA-axis hormones (ACTH, vasopressin, growth hormone, prolactin) |
| Highest available evidence | Published randomized, placebo-controlled human trials, but none measured sleep architecture as an outcome |
| Human research available | Yes: two randomized, placebo-controlled trials plus one open (unblinded) opioid-detoxification trial, all decades old |
| Development status | Studied in small Western European trials from the late 1970s through the 1990s; no modern development program |
| Regulatory status | Not approved as a drug anywhere |
Technical identity
| Primary name | DSIP (Delta Sleep-Inducing Peptide) |
| Alternative names | Delta Sleep-Inducing Peptide; “DSIP peptide” (community name); Deltalicin (intranasal formulation studied in Russia) |
| Peptide sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| Amino-acid length | 9 residues |
| Molecular formula | Not independently re-verified in this research pass |
| Molecular weight | Not independently re-verified in this research pass |
| CAS Registry Number | 62568-57-4, as commonly cited on vendor and reference material; not independently re-derived for this entry |
| PubChem CID | Not independently re-verified in this research pass |
| UNII | Not established |
| DrugBank ID | Not established |
| Chemical modifications | None reported; native isolated sequence |
| Peptide class | Endogenous nonapeptide (functional role and even existence as a distinct peptide has been questioned in the literature) |
| Primary biological target | Not conclusively established: measurable effects on ACTH secretion in one controlled trial; no confirmed receptor |
| Developer or originator | First isolated 1977 from rabbit blood; studied mainly at Western European academic centers (Italy, Germany, Switzerland) |
| Development status | Small academic trials only; never advanced to drug approval |
What it is
Delta sleep-inducing peptide, DSIP, is a nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first reported in 1977 from the blood of rabbits during electrically induced delta-wave sleep. Unlike Semax and Selank, DSIP was studied mainly in Western Europe (Italy, Germany, Switzerland) from the late 1970s through the 1990s, and unlike either of those two compounds it has genuine, published, blinded, placebo-controlled human trials. It has never been approved as a drug anywhere; its name describes the effect its 1970s discoverers proposed for it, not an established mechanism.
Potential benefits and research applications
Deep sleep induction, the effect the compound is named for and marketed on
DSIP was originally isolated for its proposed ability to induce delta-wave (deep) sleep when transferred between animals, and this remains the primary reason it is sought out today. No controlled human trial located for this entry measured sleep architecture (EEG delta activity) as an outcome, so the compound’s namesake effect has not actually been tested in the trials this entry could locate.
Evidence: has not been established in a controlled human sleep study; the claim is largely carried by the compound’s name and by community reports (Tier 6, community-reported information), not by the published trials.
HPA-axis modulation, the one effect with actual controlled human data
A 1994 randomised, placebo-controlled trial in normal men found that intravenous DSIP produced a significant decrease in ACTH levels compared with saline. This is the clearest positive, controlled human finding for DSIP located for this entry, though it was not the sleep effect the compound is best known for.
Evidence: has been shown in one randomised, placebo-controlled human trial (Tier 1, published human clinical evidence, single small study); not independently replicated in the sources reviewed here.
Opioid withdrawal support, tested only in an open, unblinded trial
An open (not blinded) 1998 clinical trial reported DSIP use in opioid detoxification. Without blinding or a placebo arm, this result cannot rule out expectation or natural-course effects.
Evidence: has been reported in one open human trial (Tier 2, human observational evidence without a controlled design); has not been established under blinded, placebo-controlled conditions.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| HPA-axis modulation (Chiodera 1994) | Intravenous | 25 nmol/kg | Single dose | Single administration over 10 minutes | Published human clinical trial (randomized, placebo-controlled) |
| Growth hormone/prolactin study (Giusti 1993) | Intravenous | 25 mcg/kg (roughly 2 mg for an 80 kg adult) | Single dose | Single administration over 30 minutes | Published human clinical trial (randomized, placebo-controlled; no significant GH/prolactin effect found) |
| Opioid detoxification (Backmund 1998) | Not detailed in the source reviewed | Not detailed in the source reviewed | Not detailed in the source reviewed | Not detailed in the source reviewed | Published human trial (open, not blinded) |
| Sleep support, general (community) | Subcutaneous or intranasal | Commonly reported as 100 to 300 mcg per dose, roughly a tenth of the per-kilogram IV trial dose, by a different route | Once nightly | Often cycled, days to a few weeks | Community / vendor reported: no controlled human sleep study exists to check this figure against |
What the human trials actually found
A 1993 randomised, placebo-controlled trial in eight healthy women found that intravenous DSIP, at a dose known to alter ECG patterns, did not change growth hormone or prolactin secretion, at rest or in response to an arginine challenge, and did not alter their circadian rhythm. A separate 1994 randomised, placebo-controlled trial in normal men found that DSIP produced a significant decrease in ACTH levels compared with saline, but did not change arginine-vasopressin secretion under osmotic or orthostatic stimulation.
An open trial (not blinded) reported DSIP used in opioid detoxification in the 1990s, and a 2014 Russian trial of “deltalicin” (DSIP given intranasally at 0.3 milligrams daily for two months) reported improved visual evoked potential recovery times in diabetic retinopathy patients, an outcome unrelated to sleep.
Reading across these studies, the consistent finding is not that DSIP reliably induces deep sleep in a dose-dependent, reproducible way; it is that DSIP has small, measurable, but inconsistent effects on the hypothalamic-pituitary-adrenal axis (lowering ACTH in one trial) without a clean effect on the growth-hormone or vasopressin axes, and no controlled trial located for this entry demonstrates the sleep-architecture effect that gives the compound its name in a rested, healthy human being. The lack of clean reproducibility across four decades of small trials is itself the finding.
What is not known
Whether DSIP reliably increases delta-wave sleep in humans at any dose, by any route, in a way that has been reproduced across independent groups. The controlled trials located for this entry did not demonstrate that effect cleanly.
A confirmed, endogenous physiological role for DSIP in humans. Its very existence as a distinct, functionally important endogenous peptide has been questioned in the literature since shortly after its discovery.
Modern human pharmacokinetics. The trials located for this entry are decades old and used routes and assays that would not meet current standards.
Frequently asked questions
What is DSIP?
DSIP, delta sleep-inducing peptide, is a nonapeptide first isolated from rabbit blood in 1977 during delta-wave sleep. It has never been approved as a drug anywhere.
How does DSIP work?
Its exact mechanism is not settled. It has been shown in one controlled human trial to lower ACTH, but no clean, reproduced effect on sleep architecture has been demonstrated, and its status as a distinct, functionally important endogenous peptide has been questioned in the literature.
What dosage has been studied in humans?
Controlled human trials used intravenous doses around 25 micrograms per kilogram (roughly 2 milligrams for an 80 kg adult) as a single dose. Neither trial tested a repeated or nightly dosing schedule.
What dosage commonly circulates online?
Community sleep-support material typically describes 100 to 300 micrograms nightly, by subcutaneous injection or intranasally, roughly a tenth of the per-kilogram intravenous dose used in the controlled trials and by an entirely different route.
Has DSIP been studied in humans?
Yes. Two randomised, placebo-controlled human trials from the early 1990s tested it, along with an open (unblinded) opioid-detoxification trial. None of the controlled trials measured sleep architecture as an outcome.
Is DSIP approved for use?
No. It has never been approved as a drug in any jurisdiction.
What routes of administration are reported?
The controlled human trials used intravenous administration. Community-reported use is by subcutaneous injection or intranasally.
Does DSIP actually improve sleep?
This has not been established. No controlled human trial located for this entry measured sleep architecture as an outcome, despite the compound’s name and its reputation as a sleep aid.
What side effects have been reported?
The controlled trials reviewed for this entry did not report a detailed adverse-event profile. No modern human safety or toxicology study was located.
What remains unknown about DSIP?
Whether it reliably increases delta-wave sleep in a healthy human being at any dose or route; whether it has a confirmed, functionally important endogenous role at all; and its modern human pharmacokinetics and safety profile.
Bottom line
DSIP is unusual among Russian-lineage nootropic peptides in actually having decades-old, blinded, placebo-controlled human trials. But those trials did not find the clean, reproducible deep-sleep effect its name implies; the clearest controlled finding is a modest drop in ACTH in normal men, and an unblinded opioid-detoxification trial adds only weak supporting evidence. The doses circulating online today, taken nightly by injection or intranasally, have no controlled human sleep study behind them at all. DSIP has never been approved as a drug anywhere.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Sleep support, general | Subcutaneous or intranasal | 100 to 300 mcg per dose | Once nightly | Often cycled, days to a few weeks |
Circulating sleep-support material for DSIP describes doses in the range of 100 to 300 micrograms nightly, by subcutaneous injection or intranasally. The controlled human trials located for this entry used intravenous dosing at 25 micrograms per kilogram, roughly 2 milligrams for an 80 kg adult in a single dose, an order of magnitude above the circulating figure and by a different route, and neither trial measured sleep architecture as its outcome. There is, in short, no controlled human study of DSIP for sleep, at any dose, that the circulating figure can be checked against.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- Giusti M, et al. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Psychoneuroendocrinology 1993;18(1):79-84. Human, randomised, placebo-controlled. PMID 8475226
- Chiodera P, et al. Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men. Horm Res 1994;42(6):267-272. Human, randomised, placebo-controlled. PMID 7698722
- Backmund M, et al. Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. J Clin Psychopharmacol 1998;18(3):257-258. Human, open (not blinded). PMID 9617990
Compare DSIP with related compounds
Research area: Neuro and cognitive.